Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
Jaya Shukla, Sejal Chopra, Komalpreet Kaur, Sudipta Chakraborty, Harmandeep Singh, Ajay Duseja, Naveen Kalra, Bhagwant Rai Mittal
Hepatocellular carcinoma (HCC) is an aggressive malignancy with a poor prognosis. Surgical resection is limited. Selective intra-arterial radionuclide therapy (SIRT) emerged as a potential cure for intermediate HCC with portal vein thrombosis. We report a pilot study of a 48-year-old man with recurrent HCC who underwent 177Lu-microsphere SIRT (2.2 GBq) in segment III. Posttherapy SPECT/CT images (24 hours to 3 months) demonstrated excellent localization and prolonged retention within the tumor. Pre- and 3-month post-SIRT CECT showed a notable decrease in arterial enhancement and tumor size...
February 7, 2024: Clinical Nuclear Medicine
#22
JOURNAL ARTICLE
Ahmed M Badheeb, Mohammed K Al Sedran, Faisal Ahmed, Ibrahim K Al Sidran, Mohammed H Al Qurayshah, Abdullah Abu Bakar, Hamoud Y Obied, Islam A Seada, Abdelaziz Aman, Mohamed Badheeb
Background Hepatocellular carcinoma (HCC) represents the most common primary liver malignancy, with a high fatality rate. Relatively, Saudi Arabia has a high incidence of HCC, which is detected in later stages with a poor prognosis. This study aims to investigate the patterns, outcomes, and mortality predictors of HCC in Saudi Arabia. Method A retrospective study from April 2018 to June 2022 included patients with HCC who were diagnosed and managed at the Najran Oncology Center, Saudi Arabia. Through our cancer registry, the patients' clinical, laboratory, radiological, and survival profiles were extracted and analyzed to assess factors associated with mortality using a univariate analysis...
January 2024: Curēus
#23
JOURNAL ARTICLE
Edo Dongelmans, Nicole Erler, Rene Adam, Silvio Nadalin, Vincent Karam, Sezai Yilmaz, Claire Kelly, Jacques Pirenne, Koray Acarli, Michael Allison, Abdul Hakeem, Dhakshinamoorthy Vijayanand, Dzmitry Fedaruk, Oleg Rummo, Murat Kilic, Arno Nordin, Lutz Fischer, Alessandro Parente, Darius Mirza, William Bennet, Yaman Tokat, Francois Faitot, Barbara B Antonelli, Gabriela Berlakovich, David Patch, Frederik Berrevoet, Marija Ribnikar, Theophile Gerster, Eric Savier, Salvatore Gruttadauria, Bo-Göran Ericzon, Andrés Valdivieso, Valentin Cuervas-Mons, Baltasar Perez Saborido, Roland S Croner, Luciano De Carlis, Giulia Magini, Roberta Rossi, Irinel Popescu, Laze Razvan, Stefan Schneeberger, Hans Blokzijl, Laura Llado, Miguel Angel Gomez Bravo, Christophe Duvoux, Vladimír Mezjlík, Gabriel C Oniscu, Kelsey Pearson, Murat Dayangac, Valerio Lucidi, Olivier Detry, Fernando Rotellar, Caroline den Hoed, Wojciech G Polak, Sarwa Darwish Murad
BACKGROUND AND AIMS: Management of Budd-Chiari Syndrome (BCS) has improved over the last decades. The main aim was to evaluate the contemporary post-liver transplant (LT) outcomes in Europe. APPROACH AND RESULTS: Data from all transplanted patients from 1976-2020 was obtained from the European Liver Transplantation Registry (ELTR). Patients<16yrs, with secondary BCS or hepatocellular carcinoma were excluded. Patient- (PS) and graft survival (GS) before and after 2000 were compared...
February 15, 2024: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
#24
JOURNAL ARTICLE
Ying Xiao, Keren Li, Ying Zhao, Shizhong Yang, Jun Yan, Canhong Xiang, Jianping Zeng, Qian Lu, Chen Zhang, Gong Li, Guangxin Li, Jiahong Dong
BACKGROUND AND AIMS: Hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) has an extremely poor prognosis. A previous study proved that low-dose radiotherapy (RT) could prolong the prognosis of HCC patients with PVTT. This study aims to explore the sensitivity of PVTT to RT treatment. METHODS: Patients were selected based on imaging diagnosis of HCC accompanied by PVTT and received combined treatment of radiotherapy, antiangiogenic drugs and immune checkpoint inhibitors, followed by hepatectomy or liver transplantation from January 2019 to August 2022...
February 14, 2024: BMC Surgery
#25
JOURNAL ARTICLE
Manuel Lim, Jongman Kim, Jinsoo Rhu, Gyu-Seong Choi, Jae-Won Joh
BACKGROUND/AIM: Hepatocellular carcinoma (HCC) tumor thrombi located in the first branch of the portal vein (Vp3) or in the main portal trunk (Vp4) are associated with poor prognosis. This study aimed to investigate the clinicopathological characteristics and risk factors for HCC recurrence and mortality following liver resection (LR) in patients with Vp3 or Vp4 HCC. METHODS: The study included 64 patients who underwent LR for HCC with Vp3 or Vp4 portal vein tumor thrombosis (PVTT)...
February 14, 2024: Journal of liver cancer
#26
JOURNAL ARTICLE
Jin-Shu Pang, Xiu-Mei Bai, Wei-Jun Wan, Tong Kang, Rong Wen, Li-Peng Li, Hai-Hui Yin, Chun-Miao Lu, Dong-Yue Wen, Yun He, Hong Yang
OBJECTIVE: Thermal ablation is a commonly used therapy for hepatocellular carcinoma (HCC). Nevertheless, inadequate ablation can lead to the survival of residual HCC, potentially causing rapid progression. The underlying mechanisms for this remain unclear. This study explores the molecular mechanism responsible for the rapid progression of residual HCC. METHODS: We established an animal model of inadequate ablation in BALB/c nude mice and identified a key transcriptional regulator through high-throughput sequencing...
2024: Journal of Hepatocellular Carcinoma
#27
REVIEW
Kanglian Zheng, Xiaodong Wang
Primary hepatobiliary cancers (PHCs), which mainly include hepatocellular carcinoma (HCC) and biliary tract cancers (BTCs), are mostly diagnosed in the advanced stage and are not candidates for curative surgery or ablation, resulting in a dismal prognosis. Targeted therapies with or without programmed death receptor 1 (PD-1)/PD-L1 inhibitors have been incorporated into first-line treatments for advanced HCC. Systemic chemotherapy is still the mainstay treatment for advanced BTCs, and combining it with PD-1/PD-L1 inhibitors has resulted in prolonged patient survival...
2024: Therapeutic Advances in Medical Oncology
#28
JOURNAL ARTICLE
Jeayeon Park, Yun Bin Lee, Yunmi Ko, Youngsu Park, Hyunjae Shin, Moon Haeng Hur, Min Kyung Park, Dae-Won Lee, Eun Ju Cho, Kyung-Hun Lee, Jeong-Hoon Lee, Su Jong Yu, Tae-Yong Kim, Yoon Jun Kim, Tae-You Kim, Jung-Hwan Yoon
BACKGROUND/AIM: Atezolizumab plus bevacizumab and lenvatinib are currently available as first-line therapy for the treatment of unresectable hepatocellular carcinoma (HCC); however, comparative efficacy studies are still limited. This study aimed to investigate the effectiveness of these treatments in HCC patients with portal vein tumor thrombosis (PVTT). METHODS: We retrospectively included patients who received either atezolizumab plus bevacizumab or lenvatinib as first-line systemic therapy for HCC with PVTT...
January 19, 2024: Journal of liver cancer
#29
JOURNAL ARTICLE
Mohamed Yousry Taher, Ehab Mostafa Hassouna, Abeer Shawky El-Hadidi, Omar Sameh El-Aassar, Mohamed Fathy Bakosh
PURPOSE: Cytokeratin 19 fragment 21-1 (CYFRA 21-1) and cytokeratin 19 fragment 2G2 (CK 19-2G2) are two soluble fragments of cytokeratin 19 (CK 19) that can be detected in serum. CK 19-positive hepatocellular carcinoma (HCC) is characterized by an aggressive behavior and a poor outcome. This study aimed to assess the prognostic value of serum CYFRA 21-1 and CK 19-2G2 in predicting tumor aggressiveness and overall survival (OS) in patients with hepatic C virus (HCV)-related HCC. METHODS: The current study included 138 patients with HCV-related HCC recruited from the Hepatobiliary and Interventional Radiology Units at Alexandria's main university hospitals and 40 healthy individuals as controls...
January 17, 2024: Journal of Gastrointestinal Cancer
#30
JOURNAL ARTICLE
Xing Wang, Jin-Ni Luo, Xiao-Ying Wu, Qi-Xian Zhang, Bin Wu
BACKGROUND: Liver cirrhosis (LC) is a prevalent and severe disease in China. The burden of LC is changing with widespread vaccination of hepatitis B virus (HBV) and antiviral therapy. However, the recent transition in etiologies and clinical features of LC cases requiring hospitalization is unclear. AIM: To identify the transition in etiologies and clinical characteristics of hospitalized LC patients in Southern China. METHODS: In this retrospective, cross-sectional study we included LC inpatients admitted between January 2001 and December 2020...
December 27, 2023: World Journal of Hepatology
#31
Pramod Kumar, Pradeep Krishna, Ravindra Nidoni, C K Adarsh, M G Arun, Aashish Shetty, J Mathangi, Sandhya, Mahesh Gopasetty, B Venugopal
Atezolizumab plus bevacizumab is the preferred first-line treatment regimen for patients with advanced hepatocellular carcinoma. Limited data have shown promising results with the use of immune checkpoint inhibitors like nivolumab to downstage these patients for liver transplantation (LT). Here, we describe the first case of successful downstaging with atezolizumab plus bevacizumab in a patient with multifocal hepatocellular carcinoma and main portal vein tumoral thrombosis, followed by ABO-incompatible live donor LT...
January 12, 2024: American Journal of Transplantation
#32
JOURNAL ARTICLE
Lorenz Balcar, Arpad Mrekva, Bernhard Scheiner, Katharina Pomej, Tobias Meischl, Mattias Mandorfer, Thomas Reiberger, Michael Trauner, Dietmar Tamandl, Matthias Pinter
BACKGROUND & AIMS: The value of bleeding prophylaxis and anticoagulation in patients with hepatocellular carcinoma (HCC) and macrovascular tumour invasion (MVI) is unclear. We evaluated the impact of anticoagulation on thrombosis progression, bleeding events, and overall mortality, and assessed the efficacy of adequate management of varices as recommended for patients with cirrhosis. METHODS: HCC patients with MVI who had Child-Turcotte-Pugh A-B7 were included between Q4/2002 and Q2/2022...
January 13, 2024: Cancer Imaging: the Official Publication of the International Cancer Imaging Society
#33
RANDOMIZED CONTROLLED TRIAL
Etienne Garin, Lambros Tselikas, Boris Guiu, Julia Chalaye, Yan Rolland, Thierry de Baere, Eric Assenat, Vania Tacher, Xavier Palard, Desirée Déandreis, Denis Mariano-Goulart, Giuliana Amaddeo, Karim Boudjema, Antoine Hollebecque, Mohamad Azhar Meerun, Helen Regnault, Eric Vibert, Boris Campillo-Gimenez, Julien Edeline
Interim analysis of the DOSISPHERE-01 study demonstrated a strong improvement in response and overall survival (OS) on using 90 Y-loaded glass microspheres with personalized dosimetry compared with standard dosimetry in patients with nonoperable locally advanced hepatocellular carcinoma. This report sought to provide a long-term analysis of OS. Methods: In this phase II study (ClinicalTrials.gov identifier NCT02582034), treatment was randomly assigned (1:1) with the goal to deliver either at least 205 Gy (if possible >250-300 Gy) to the index lesion in the personalized dosimetry approach (PDA) or 120 ± 20 Gy to the treated volume in the standard dosimetry approach (SDA)...
February 1, 2024: Journal of Nuclear Medicine
#34
JOURNAL ARTICLE
Khai Viet Ninh, Dang Hai Do, Trung Duc Nguyen, Phuong Ha Tran, Tuan Hoang, Dung Thanh Le, Nghia Quang Nguyen
BACKGROUNDS/AIMS: Liver transplantation (LT) provides a favorable outcome for patients with hepatocellular carcinoma (HCC) and was launched in Vietnam in 2004. In this study, we evaluated the short-term and long-term outcomes of LT and its risk factors. METHODS: This retrospective study analyzed HCC patients who underwent LT at Viet Duc University hospital, Vietnam, from 01/2012-03/2022. The following data were gathered: demographics, virus infection, tumor characteristics, alpha-fetoprotein (AFP) level, Child-Pugh and MELD scores, selection criteria, type of LT, complications, 30-day mortality, and disease-free and overall survival (DFS and OS)...
January 9, 2024: Annals of Hepato-Biliary-Pancreatic Surgery
#35
JOURNAL ARTICLE
Xiao Cheng, Yujun Tang, Qinjun He, Jiankang Song, Kunyuan Wang, Hui Li, Jing Huang, Weibin Wang, Junying Li, Haiyu Wang, Minghan Tu, Jinzhang Chen, Guosheng Yuan, Shuai Kang, Hongyan Liu, Xiaoyong Zhang, Wenfan Luo, Yali Ji, Xiaoqin Lan, Ling Zhou, Qintao Lai, Xiaoqin Luo, Qiaoping Wu, Damei Zhou, Yingqi Tan, Jinjun Chen, Xiaofeng Zhang
BACKGROUND: Esophagogastroduodenoscopy (EGD) is required to screen for high-risk varices (HRV) in patients with hepatocellular carcinoma (HCC), especially since overall survival rates have dramatically improved with new systemic therapies. AIM: To assess the Baveno VI and Baveno VII algorithms' ability to rule out HRV in hepatitis B virus (HBV)-related HCC METHODS: We prospectively enrolled consecutive patients with HBV related, compensated cirrhosis and newly diagnosed HCC who underwent liver stiffness measurement, spleen stiffness measurement (SSM) using a 100-Hz shear wave frequency, and EGD...
December 28, 2023: Alimentary Pharmacology & Therapeutics
#36
EDITORIAL
Chao-Long Chen, Leona Bettina P Dungca, Chee-Chien Yong, Itsuko Chih-Yi Chen, Yu-Fan Cheng, Jen-Yu Cheng, Yen-Yang Chen
No abstract text is available yet for this article.
December 1, 2023: Hepatobiliary Surgery and Nutrition
#37
JOURNAL ARTICLE
Raghuraman Soundararajan, A B Pooja, Pankaj Gupta, Ajay Gulati, Naveen Kalra, Shravya Singh, Madhumita Premkumar, Sunil Taneja, Vaneet Jearth, Vishal Sharma, Ajay Duseja
BACKGROUND/AIM: Hepatocellular carcinoma (HCC) surveillance is recommended in nonalcoholic fatty liver disease (NAFLD)-related cirrhosis. The performance of ultrasound (US) is impaired in NAFLD. This study aimed to evaluate the diagnostic performance of non-contrast abbreviated magnetic resonance imaging (AMRI) for HCC detection in NAFLD. METHODS: Consecutive contrast-enhanced magnetic resonance imaging (CE-MRI) scans of NAFLD patients between June 2017 and December 2021 were retrieved...
2024: Journal of Clinical and Experimental Hepatology
#38
JOURNAL ARTICLE
Zhipeng Lin, Du Chen, Xiaolong Hu, Dabei Huang, Yuan Chen, Jian Zhang, Xiaoqun Li, Xugong Zou
This study aimed to evaluate the clinical efficacy of hepatic arterial infusion chemotherapy (HAIC) combined with lenvatinib and PD1 inhibitors vs. transarterial chemoembolization (TACE) combined with lenvatinib and PD1 inhibitors in the treatment of unresectable hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) and artery-portal shunts (APFs). HCC Patients with PVTT and APFs who received HAIC in combination with PD1 inhibitor or TACE in combination with lenvatinib and PD1 inhibitor from March 2019 to May 2023 in Zhongshan People's Hospital were included...
2023: American Journal of Cancer Research
#39
JOURNAL ARTICLE
Anant Ramaswamy, Anand Kulkarni, George John, Amit Rauthan, Shekhar Patil, Ajay Duseja, Vineet Talwar, Senthil J Rajappa, Nikhil Ghadyalpatil, Manav Wadhawan, Akash Shukla, Vamshi M Krishna, Sujay Srinivas, Sunil Taneja, K Mary Sravani, Sahaj Rathi, Prabhat Bhargava, Vikas Ostwal
PURPOSE: Immune checkpoint inhibitors (ICIs) is the initial line of management in advanced hepatocellular carcinoma (HCC), but survivals in the real world are not known. MATERIALS AND METHODS: A retrospective study of patients with advanced HCC receiving ICIs (as first-line therapy or as later lines of therapy) across 11 Indian institutions was conducted. Patients were divided into either cohort 1 (trial-like receiving ICI as first-line therapy), with a Child Pugh score (CTP) of ≤6, an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0/1, and no VP4 (main portal vein thrombosis [MPVT]) or cohort 2 (trial unlike) who did not satisfy at least one of the above criteria...
September 2023: JCO global oncology
#40
JOURNAL ARTICLE
Mahrukh Ali, Om Parkash
Background: Hepatocellular carcinoma (HCC) is a major cause of morbidity and mortality in patients with chronic liver diseases (CLDs). Studies have shown a correlation between low serum albumin levels and the aggressiveness of liver cancer. We aimed to determine the prevalence of hypoalbuminemia and its relationship with HCC aggressiveness in our patients. Methods: This study was conducted retrospectively, and data were gathered from the gastroenterology unit of the Department of Medicine at the Aga Khan University Hospital in Karachi, Pakistan...
July 2023: Middle East Journal of Digestive Diseases
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
